Routine genetic testing in patients with pancreatic cancer - worth it?

Abstract

Background: Approximately 5-10% of patients with pancreatic adenocarcinoma (PDAC) carry germline mutations that contributed to the development of their cancer. Recently, the National Comprehensive Cancer Network (NCCN) began recommending that all pancreatic cancer patients and first-degree relatives undergo genetic testing. For patients who were previously unaware of their germline mutation, such findings may have significant impact on the patient’s family and family planning. The aim of this study was to investigate the frequency of new diagnoses of germline mutations in pancreatic cancer and characterize their oncologic outcomes.